Moleculin Biotech is a clinical stage pharmaceutical company. Co.'s technologies include: Annamycin, an anthracycline designed to be different than existing approved anthracyclines by eliminating cardiotoxicity and avoiding the multidrug resistance mechanisms that can limit the efficacy of the approved products; WP1066 Portfolio, which includes WP1066 and WP1220, two of several Immune/Transcription Modulators in the portfolio designed to inhibit phosphorylated signal transducer and activator of transcription among other transcription factors associated with tumor activity, while also stimulating a natural immune response to tumors by inhibiting the errant activity of Regulatory T-Cells. The MBRX stock yearly return is shown above.
The yearly return on the MBRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MBRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|